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ABSTRACT
Background: Incidence of whooping cough is increasing in Korea. Since 2011, occurrence 
among adolescents and adults has risen putting vulnerable neonates at risk. National 
immunization guidelines now include Tdap (tetanus toxoid, reduced diphtheria toxoid, 
and acellular pertussis) vaccination during pregnancy and as a cocooning strategy (i.e., 
vaccinating adults and adolescents in contact with neonates). This study assessed post-
marketing Tdap (Boostrix®, GSK, Belgium) vaccine safety in subjects ≥ 10 years.
Methods: This open, non-comparative multi-center study was conducted over six years at 
10 hospitals in Korea.  Subjects received Tdap in normal clinical practice according to local 
prescribing information. All adverse events (AEs) were recorded, classified as expected or 
unexpected, and severity and relationship to Tdap were assessed.
Results: The analysis included 672 Korean subjects (mean age, 44 years; range, 11–81), 451 were 
women and 211 were pregnant. Ninety subjects experienced 124 AEs (incidence 13.39%) of which 
six were serious AEs (SAEs) assessed as not related to vaccination, and 51 were non-SAEs related to 
vaccination (mostly administration site reactions). Overall 65/124 AEs were unexpected; the most 
common were 14 constipation, 5 dyspepsia, 4 common cold and 4 premature labor cases. One 
case of common cold was assessed as possibly related to vaccination. Pregnancy outcome was ‘live 
infant, no apparent congenital anomaly’ in 195 subjects (92.42%) or ‘lost to follow-up’ in 16 subjects.
Conclusion: Tdap administration to Korean subjects ≥ 10 years, including pregnant women, 
for the prevention of diphtheria, tetanus and pertussis was shown to have a well-tolerated 
safety profile.
Trial Registration: ClinicalTrials.gov Identifier: NCT01929291
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INTRODUCTION
Pertussis, or whooping cough, is a respiratory illness caused by infection with highly 
contagious Bordetella pertussis. Infants are at particular risk of infection before completing 
the primary DTaP (diphtheria toxoid, tetanus toxoid and acellular pertussis) vaccination, 
and also experience the highest rates of morbidity and mortality compared to the rest of 
the population.1 The incidence of pertussis tends to peak every 3–5 years, although several 
countries have reported an increase in the overall incidence of disease in older children, 
teenagers and adults, prompting expansions to the available vaccination programs in the 
past ten years.2-4 The tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis 
booster vaccine (Tdap, Boostrix®; GSK, Rixensart, Belgium) was licensed in 2005 for use in 
adolescents and adults in the United States (US),5 and recommendations were expanded 
to include pregnant women since 2011 to stimulate maternal antibody transfer for the 
protection of neonates.2,6,7 A similar program was implemented in the United Kingdom 
(UK) in 2012 following a sharp increase in pertussis cases.8,9 Cocooning strategies, involving 
vaccination of parents and others in close contact with newborns, were also attempted 
although proved logistically difficult to implement.2,3,10
The disease burden of pertussis in Korea declined substantially with the implementation of 
infant DTaP vaccination in 1982, and Tdap registration for adults and adolescents in 2010. As 
in other countries, however, recent outbreaks occurred in 2012 and 2015, and the incidence 
is continuing to rise in 2018. The most recent reports from the Korean Centers for Disease 
Control and Prevention (KCDC) show 230 confirmed cases in 2012, 205 in 2015 and 318 in 
2017.11 Routine passive surveillance during 2001–2012, and ad hoc active sentinel surveillance 
during the 2012 outbreak, showed infants under one year of age had the highest age-specific 
incidence of pertussis.12 A noticeable increase in the proportion of adolescents and adults 
(> 20 years) with pertussis was observed after 2011.12 As a result, the KCDC recently updated 
their immunization guidelines to include Tdap vaccination of pregnant women and of adults 
and adolescents in close contact with infants, in order to reduce the risk to neonates and 
young infants.13
In Korea, Tdap vaccine is indicated for adolescents and adults older than 10 years of age, for 
the prevention of diphtheria, tetanus, and pertussis. Tdap or Td (without acellular pertussis) 
is included in the National Immunization Program for adolescents aged 11–12 years.14 The 
primary series for infants includes DTaP with polio vaccine at ages 2, 4 and 6 months, with 
one booster dose of DTaP each at 15–18 months and 4–6 years of age.15
The aim of this study was to assess the safety of Tdap (Boostrix®; GSK) in pre-adolescents, 
adolescents, adults (including pregnant women), and older adults (65 years or older), when 
administered in routine practice in the post-marketing setting. The incidence of adverse 
events (AEs), including unexpected and serious AEs (SAEs), and factors considered to affect 
the safety of Tdap vaccination were collected. This study was conducted in compliance with 
regulatory requirements of the Ministry of Food and Drug Safety (MFDS).
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METHODS
Study design
This post-marketing surveillance was an open, non-comparative multi-center study 
conducted between 9 June 2010 and 8 June 2016 at ten hospitals in Korea (NCT01929291). 
Consecutive subjects who received a single dose of Tdap (Boostrix®; GSK) in routine clinical 
practice, administered according to the local prescribing information (PI), were included in 
the total vaccinated cohort.
In addition to the safety assessment, the following data were collected: subject demographics, 
medical and vaccination history, study vaccine administration status, concomitant medication 
and vaccinations, hepatic and renal disorders. This study was designed to investigate all AEs 
occurring during the surveillance period (30-day period following vaccination), including AEs 
with unestablished causal relationships to Tdap, extremely low frequency or unexpected AEs.
Vaccination
Each prefilled syringe dose of 0.5 mL Tdap (Boostrix®; GSK) vaccine contains a sterile 
suspension of diphtheria toxoid, tetanus toxoid and three purified antigens of B. pertussis 
(pertussis toxoid, pertussis filamentous haemagglutinin and pertactin) adsorbed onto 
aluminum salts. A single dose was administered to subjects by intramuscular injection 
according to standard clinical practice and regulations.
Safety assessments
Any AE occurring in the 30-day period following vaccination was recorded in diary cards and 
evaluated internally as expected (AEs included in the PI) or unexpected according to the PI. 
Each AE was rated as: mild (easily tolerated by the subject, causing minimal discomfort and 
no interference with daily activities), moderate (sufficiently discomforting to interfere with 
normal daily activities; fever between 38°C and 39°C), or severe (preventing normal daily 
activities, fever over 39°C). Investigators categorized the relationship of each AE to the study 
vaccine as: certain, probable, possible, unlikely, conditional or unassessable/unclassifiable. 
The definitions of causality assessment were based on the guidance by Korean authorities.16 
An AE categorized as ‘unlikely’ was not considered to be an adverse drug reaction (ADR). An 
SAE was defined as any AE that: results in death, is life threatening, requires hospitalization 
or prolongation of existing hospitalization, results in disability, or, is a congenital anomaly/
birth defect in the offspring of a study subject.
Statistical analysis
Statistical analyses were performed on the total vaccinated cohort. AEs and SAEs based on 
the World Health Organization-Adverse Reactions Terminology dictionary and stratified by 
expected and unexpected were analyzed with exact 95% confidence intervals. All statistical 
analyses were conducted on the Statistical Analysis Systems (SAS Inst., Cary, NC, USA). The 
χ2 test and Fisher's exact test were used to calculate P values.
Ethics statement
The study was conducted in accordance with regulatory requirements and the local rules 
and regulations of the Korean MFDS17. The study protocol was reviewed and approved by the 
independent ethics committee at each study center including Severance Hospital (IRB No. 
4-2013-0236). Subjects or parents/guardians of subjects provided written informed consent 
for the collection and handling of personal and safety information before study enrolment.
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RESULTS
Data from 672 subjects were assessed for safety, while data from 10 subjects who did not 
fulfill inclusion/exclusion criteria were analyzed separately. There were no pediatric, geriatric 
or pregnant subjects, or cases with a hepatic or renal disorder among the 10 separately 
analyzed subjects. All 672 subjects in the safety analysis were Korean. There were 451 women 
subjects (67.11%) of which 211 (46.78%) were pregnant. The mean age of subjects was 44.38 ± 
14.76 years, ranging from 11 to 81 years of age (Table 1).
During the entire surveillance period, 90 subjects experienced 124 AEs, resulting in an AE 
incidence of 13.39%. A majority of AEs (58.87%) were unlikely to be related to vaccination, 
while 51 events in 35 subjects (5.21%) were assessed by clinicians as related (i.e., 8 
certainly, 23 probably, and 20 possibly) to vaccination (i.e., 51 ADRs). These included 40 
administration site reactions in 30 subjects, three respiratory events in two subjects possibly 
related to vaccination (i.e., common cold, coughing, rhinorrhea), one subject each with 
diarrhea, fever, chills, fatigue, rash, and, arthralgia, and two subjects with myalgia. The 
most common AEs assessed as not related to vaccination were; 14 constipation events, 14 
respiratory system events (e.g., common cold and coughing) and 13 women reproductive 
disorder events (e.g., premature labor, leukorrhea, vaginal hemorrhage). Six SAEs occurred 
in six subjects (0.89%). Two subjects had a vaginal hemorrhage, and one subject each 
had gastroenteritis, premature birth, genital infection, and, fever. All except fever were 
unexpected SAEs (Table 2). None of the SAEs were assessed as related to vaccination. 
(Supplementary Table 1).
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Table 1. Demographic data
Variables No. of subjects (%)
Gender
Men 221 (32.89)
Women 451 (67.11)
Ethnicity
Korean 672 (100.00)
Pregnancy
Yes 211 (46.78)
No 240 (53.22)
Age, yr
Mean ± SD 44.38 ± 14.76
Median 38
Range 11–81
Age groups, yr
< 20 7 (1.04)
20–29 64 (9.52)
30–39 281 (41.82)
40–49 73 (10.86)
50–59 110 (16.37)
≥ 60 137 (20.39)
≥ 75 18 (2.68)
Age categories, yr
Child: 10–11 1 (0.15)
Adolescent: 12–18 4 (0.60)
Adult: 19–64 604 (89.88)
Older adults: ≥ 65 63 (9.38)
SD = standard deviation.
Of the 118 non-SAEs, 94.92% were classed as mild, and the remaining six AEs as moderate 
(i.e., three injection site events, one case each of common cold, pre-eclampsia, and rash). 
Most AEs (73.73%) did not result in medically-attended visits, however, one subject with 
enterocolitis went to the Emergency room, and medical personnel were consulted for 30 AEs 
(25.42%). In most cases, subjects recovered from the AE (120/124 AEs, 96.77%) but recovery 
status was unknown for 4 AEs (i.e., one case each of gastroesophageal reflux, premature 
birth, arthralgia, and pyuria).
Overall, 54 subjects (8.04%) had 65 unexpected AEs; five subjects (0.74%) had an unexpected 
SAE assessed as not related to vaccination, while eight subjects (1.19%) had 10 unexpected 
non-serious ADRs (Table 2). The most commonly observed unexpected AEs assessed as 
not related to vaccination were 24 gastrointestinal system disorders (e.g., constipation 
in 14 subjects, 2.08%), followed by 13 women reproductive disorder events as described 
previously and, eight respiratory system disorders (e.g., three cases of common cold, two of 
dyspnea and two of pleural effusion). Unexpected SAEs included two subjects with vaginal 
hemorrhage and one each with premature birth, genital infection and gastroenteritis. The 
most common ADR was seven injection site events in six subjects, followed by one subject 
with a common cold, one with rhinorrhea and one with chills (Table 3).
5/10https://jkms.org https://doi.org/10.3346/jkms.2019.34.e105
Post-Marketing Safety Surveillance of Tdap in Korea
Table 2. Summary of events over the study period (n = 672 total vaccinated cohort)
Variables No. of AEs No. of subjects (%) 95% CI (for the % of subjects)
AEs total 124 90 (13.39) 10.91–16.20
Unexpected AEs 65 54 (8.04) 6.09–10.35
SAEs 6 6 (0.89) 0.33–1.93
Unexpected SAE 5 5 (0.74) 0.24–1.73
ADRs total 51 35 (5.21) 3.65–7.17
Unexpected ADR 10 8 (1.19) 0.52–2.33
SADR 0 0 (0) 0.00–0.55
CI = confidence interval, AE = adverse event, SAE = serious adverse event, ADR = adverse drug reaction, SADR = 
serious adverse drug reaction.
Table 3. Most frequent unexpected AEs reported in ≥ 2 cases (n = 672 total vaccinated cohort)
Unexpected AEs No. of AEs Subjects Related to 
vaccinationNo. (%) 95% CI (for the % of subjects)
Application site disorders
Injection site pruritus 3 3 (0.45) 0.09–1.30 2 Probable
1 Possible
Injection site rash 2 2 (0.30) 0.04–1.07 1 Probable
1 Possible
Gastrointestinal disorders
Constipation 14 14 (2.08) 1.14–3.47 Unlikely
Dyspepsia 5 5 (0.74) 0.24–1.73 Unlikely
Enterocolitis 2 2 (0.30) 0.04–1.07 Unlikely
Respiratory system disorders
Common cold 4 4 (0.60) 0.16–1.52 1 Possible
Dyspnea 2 2 (0.30) 0.04–1.07 Unlikely
Pleural effusion 2 2 (0.30) 0.04–1.07 Unlikely
Women reproductive disorders
Premature labor 4 4 (0.60) 0.16–1.52 Unlikely
Leukorrhea 2 2 (0.30) 0.04–1.07 Unlikely
Vaginal hemorrhage 2 2 (0.30) 0.04–1.07 Unlikely
Urinary system disorders
Pyuria 2 2 (0.30) 0.04–1.07 Unlikely
AE = adverse event, CI = confidence interval.
Safety analysis in special populations
In terms of special populations with AEs, the study included five pediatric subjects (< 19 years) 
(three of them reported an AE: injection site pruritus, injection site pain, and headache), 63 
geriatric subjects aged 65 years or older (12 of them reported 16 AEs), 18 geriatric subjects aged 
75 years and over (three of them reported five AEs), 211 pregnant subjects (45 of them reported 
59 AEs unrelated to vaccination), 13 subjects with renal disorders (two of them reported two 
mild injection site ADRs), and, 51 subjects with hepatic disorders (10 of them reported 9 
injection site ADRs and 4 AEs unrelated to vaccination). The difference in AE incidence was not 
statistically significant by presence of renal disorder (P = 0.689) or hepatic disorder (P = 0.175).
Safety analysis was conducted in 211 pregnant women (mean age, 33.10 ± 3.32 years; ranging 
from 25 to 43 years), of which 50.2% had previous pregnancies. The mean gestational 
week was 38 ± 2 weeks at the time of Tdap vaccination, ranging from 26 to 41 weeks. Nearly 
half (48.34%) had a medical condition at the time of pregnancy, the most frequent being 
‘pregnancy, puerperium, and perinatal conditions’ in 67 subjects (65.69%), followed by 
‘endocrine disorders’ in 23 subjects (22.55%) and ‘gastrointestinal disorders’ in 19 subjects 
(18.63%). Pregnancy outcome of ‘live infant, no apparent congenital anomaly’ was observed 
in 195 subjects (92.42%) and ‘lost to follow-up’ in 16 subjects (7.58%). The infants' mean 
birth weight was 2,943 ± 623 g, ranging from 660 to 4,440 g.
A total of 45 pregnant subjects reported 59 AEs, resulting in an AE incidence of 21.33%. None 
of the reported AEs was an ADR. Most AEs were classed as unexpected (46 AEs reported by 39 
subjects). The most frequent unexpected AE (6.64%) was constipation in 14 subjects, followed 
by dyspepsia and premature labor each in 4 subjects (1.90% each), and dyspnea, pleural 
effusion, leukorrhea, vaginal hemorrhage, and pyuria, each in 2 subjects (0.95% each). There 
were six SAEs in six pregnant subjects (2.84%), none were SADRs. Two subjects had a vaginal 
hemorrhage (0.95%) and 1 subject each (0.47% each) had gastroenteritis, premature birth, 
genital infection, and fever. Women with a medical condition at the time of pregnancy were 
significantly more likely to report AEs than those without a medical condition (45 AEs in 32 
subjects with conditions versus 14 AEs in 13 subjects without, P = 0.001). Most AEs occurred 
among subjects with ‘pregnancy, puerperium, and perinatal conditions’, followed by those 
with ‘gastrointestinal disorders’ and finally ‘endocrine disorders’.
Factors affecting safety
The results indicated differences in the incidence of AEs for six factors including: gender, 
pregnancy, current medical history, concomitant medication, concomitant vaccination, and 
age group (Table 4). Vaccination history was not found to affect safety. In the month prior to 
vaccination, 32 subjects (4.8%) were administered other vaccines; primarily against typhoid 
(26 subjects, 81.25%) followed by hepatitis vaccines (12 subjects, 37.50%), measles vaccines (9 
subjects, 28.13%), and influenza and papillomavirus vaccines (4 subjects each, 12.5% each).
The AE incidence by gender was higher among women (15.96%) than men (8.14%) (P = 0.005). 
The incidence of AEs among pregnant women (21.33%) was higher than among non-pregnant 
women (11.25%) (P = 0.004).
Overall, 64.14% of subjects in the study had a current medical history; the most common 
were related to metabolism and nutrition (e.g., diabetes, overweight, osteoporosis, vitamin 
D deficiency) in 217 subjects, followed by vascular in 151 subjects (e.g., atherosclerosis, 
hypertension, coronary artery stenosis), gastrointestinal in 123 subjects, endocrine in 106 
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subjects, musculoskeletal and connective tissue in 93 subjects, psychiatric disorders in 87 
subjects, pregnancy, puerperium, and perinatal conditions in 53 subjects, and, reproductive 
system and breast disorders in 46 subjects. The AE incidence was higher among subjects with 
a current medical history (16.24%) than in subjects without (8.30%) (P = 0.004).
A total of 445 subjects (66.22%) used concomitant medications, the most common were for 
the cardiovascular and hematopoietic system in 254 subjects, central nervous system in 228 
subjects and gastrointestinal and hepatobiliary system in 226 subjects. The incidence of AEs 
was higher among subjects using concomitant medication (16.63%) compared with subjects 
without concomitant medications (7.05%) (P = 0.001).
A total of 128 subjects (19.05%) had one or more concomitant vaccinations, the most 
common being influenza vaccines in 101 subjects, pneumococcal vaccines in 16 subjects 
and varicella zoster vaccines in 8 subjects. The incidence of AEs was higher among subjects 
without concomitant vaccinations (15.63%) than among those with concomitant vaccinations 
(3.91%) (P = 0.001).
The incidence of AEs was 12.42% among adults aged 19–64 years and 19.05% among older 
adults (65 years and over). Very few children and adolescents were enrolled in the study. Two 
AEs were reported in 2/4 adolescent subjects and 1 AE in 1/1 child subject (P = 0.009).
There were 10 subjects excluded from the safety analysis set as the study vaccine was 
not administered according to the prescription information in Korea (i.e., study vaccine 
administered into the buttock): four of these subjects experienced five AEs (i.e., injection 
site pain, common cold, myalgia and two generalized weakness events). Of those, three were 
ADRs (i.e., injection site pain, generalized weakness and myalgia). No SAE was reported.
DISCUSSION
This six-year post-marketing surveillance in Korea monitoring the safety of Tdap (Boostrix®; 
GSK) in children, adolescents and adults demonstrated an acceptable safety profile of the 
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Table 4. Incidence of AEs by background factors
Variables Total vaccinated cohort  
(n = 672)
No. of AEs No. of subjects with AE % of AEs  
(95% CI)
P values
Gender Men (n = 221) 25 18 8.14 (4.90–12.57) 0.005
Women (n = 451) 99 72 15.96 (12.71–19.68)
Age group, yr 10–11 (n = 1) 1 1 100.00 (2.50–100) 0.009
12–18 (n = 4) 2 2 50.00 (6.76–93.24)
19–64 (n = 604) 105 75 12.42 (9.89–15.31)
≥ 65 (n = 63) 16 12 19.05 (10.25–30.91)
Geriatric group, yr < 75 (n = 654) 119 87 13.30 (10.79–16.15) NS (0.722)
≥ 75 (n = 18) 5 3 16.67 (3.58–41.42)
Current medical history Yes (n = 431) 100 70 16.24 (12.89–20.07) 0.004
No (n = 241) 24 20 8.30 (5.14–12.53)
Concomitant medication Yes (n = 445) 103 74 16.63 (13.29–20.42) 0.001
No (n = 227) 21 16 7.05 (4.08–11.19)
Concomitant vaccination Yes (n = 128) 5 5 3.91 (1.28–8.88) 0.001
No (n = 544) 119 85 15.63 (12.68–18.95)
Pregnant women Yes (n = 211) 59 45 21.33 (16.00–27.48) 0.004
No (n = 240) 65 27 11.25 (7.55–15.94)
CI = confidence interval, AE = adverse event, NS = non significant.
vaccine. The overall incidence of any AE was 13.39%, of which unexpected AEs occurred in 
8.04% of subjects, and there were six SAEs, none of which were related to vaccination. The 
incidence of AEs for which the causal relationship to vaccination could not be ruled out was 
5.21%, of which the majority were mild administration site reactions.
As this was an observational study of routine clinical practice, many subjects had a current 
medical condition (64%) or used concomitant medication (66%). Subjects with these 
factors had a higher incidence of AEs, as did women versus men, pregnant women versus 
non-pregnant women or older adults versus other adult groups. The incidence of AEs 
among children and adolescents should be interpreted with caution given the low number 
of subjects in these age groups (i.e., four adolescents and one child). The difference in AE 
incidence by gender was consistent with previous diphtheria or tetanus vaccine studies which 
also reported a higher rate of adverse reactions in women than in men.18 Given the nature of 
post-marketing surveillance, and due to possible confounding variables, it was not possible 
to determine the clinical significance of these factors alone on AE incidence.19
Safety data were available for special populations such as pregnant women. AEs occurred in 
21.33% of pregnant women (constipation was most frequently reported) and were assessed as 
not related to vaccination. Having a current medical condition during pregnancy was associated 
with a higher risk of AEs. Six pregnant women reported a SAE including two cases of vaginal 
hemorrhage and a premature birth, none of which were assessed as related to vaccination. A 
recent study has found that more women in Korea are having children at an older age, and with 
increased risks of preterm delivery observed in women aged over 30 years, or low birth weight 
babies for mothers over 35 years old.20 The safety of Tdap vaccination in pregnant women has not 
been previously assessed in Korea, however, data from large US2,6 and UK8 studies have not found 
an increased risk of AEs following Tdap vaccination during pregnancy. In a randomized double-
blind placebo-controlled trial assessing the safety of maternal Tdap vaccination in infants, there 
were no AEs or negative impact on infant growth and development versus controls (infants of 
mothers not vaccinated with Tdap during pregnancy).3 In large retrospective observational studies 
in the UK and the US covering over 46,000 women, maternal Tdap vaccination was not associated 
with any increased risk of preterm birth, small for gestational age (SGA) birth or any other AEs 
related to pregnancy or to any differences in neonatal outcomes such as birth weight, compared 
with unvaccinated subjects.3,6,8 In fact, one study in the US of over 7,000 pregnant women 
vaccinated with Tdap found no adverse pregnancy, delivery, or neonatal outcomes associated 
with vaccination, but a significantly higher average gestational age at delivery, fewer births before 
35 weeks of gestation, a shorter duration of neonatal hospitalization, and a lower incidence of 
SGA neonates.2 Routine Tdap vaccination has been recommended by the CDC in the US since 
2011 during each pregnancy, and it is currently also recommended in other countries (e.g., New 
Zealand, Australia, the UK, Belgium, Brazil, Mexico, and Argentina).21-25
Post-marketing safety data from a retrospective database review in 10–18 year old adolescents 
(n = 13,427) given Tdap in routine practice in the US found no increased risk of medically-
attended neurologic or hematologic events, allergic reactions, chronic illnesses or deaths 
following Tdap, compared with matched historical controls given Td (tetanus, diphtheria) 
vaccination.19
This study was unique in that it assessed the safety of Tdap (Boostrix®; GSK) among Koreans 
vaccinated in a real-world setting that included pregnant women. This observational study 
collected safety data from routine clinical practice. Given the design and nature of the post-
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marketing surveillance, results should be interpreted cautiously, as there was no control 
group and it was not possible to control for confounding factors.
In this six-year post-marketing surveillance, administration of Tdap (Boostrix®; GSK) to 
adults and children 10 years or older, including pregnant women, for the prevention of 
diphtheria, tetanus and pertussis is shown to have a well-tolerated safety profile. In the 
future, AEs and their causal relationship to Tdap will continue to be monitored through 
routine spontaneous reporting.
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